出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年7月
病理学市場における AI：コンポーネント (ソフトウェア、スキャナー)、ニューラルネットワーク (CNN、GAN、RNN)、用途 (創薬、診断、予後、ワークフロー、教育)、エンド ユーザー (製薬、バイオテクノロジー、病院検査室、研究)、地域別 – 2028年までの世界予測
AI in Pathology Market by Component (Software, Scanners), Neural Network (CNN, GAN, RNN), Application (Drug Discovery, Diagnosis, Prognosis, Workflow, Education), End User (Pharma, Biotech, Hospital Labs, Research), & Region – Global Forecast to 2028
| ページ数 | 199 |
| 図表数 | 161 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The global AI in pathology market is projected to reach USD 49 Million by 2028 from USD 24 Million in 2023, at a high CAGR of 15.6% during the forecast period. The AI in pathology market refers to the sector within the healthcare industry that encompasses the development, deployment, and utilization of artificial intelligence (AI) technologies specifically designed for pathology applications. AI models can analysed clinical data, genomic information, and pathology images to predict patient prognosis and disease progression. These models assist in personalized treatment planning, identifying high-risk patients, and optimizing healthcare resource allocation. It involves the use of advanced computational algorithms, machine learning techniques, and computer vision methods to analyse pathology images, extract relevant information, and assist pathologists in diagnostic decision-making.
“The drug discovery segment accounted for the largest share during the forecast period, by application.”
In 2022, the drug discovery segment held the largest share of the AI in pathology market. The significant growth in this segment can be attributed to various factors, including the advancements in high throughput screening and imaging technologies, the increasing utilization of AI in toxicology testing for illicit drugs, the rising expenditure on pharmaceutical and biotechnology research and development (R&D), and the ability of AI in pathology to accelerate the development of new therapeutics, improve diagnostic accuracy, and enhance approaches to personalized medicine. These factors contribute to the substantial share of the drug discovery application segment in the AI in pathology market.
“Pharmaceutical and biotechnology companies is the fastest growing end-user segment in the AI in pathology market in 2022.”
The AI in pathology market is divided into different end-user segments, including pharmaceutical and biotechnology companies, hospitals and reference laboratories, and academic and research institutes. Among these, the pharmaceutical and biotechnology companies segment is projected to witness the highest growth rate during the forecast period. This segment’s significant share and rapid growth can be attributed to the advancement of drug discovery and development processes, as well as the increasing utilization of AI in pathology for drug toxicology testing. Biotechnology companies rely on AI-based digital pathology for various purposes, including biobanking, biopharmaceutical studies, molecular assays, and the development of individualized medicine.
“North America to witness the highest growth rate and accounted for largest share during the forecast period.”
During the forecast period, the North America market is anticipated to exhibit the highest growth rate. The growth of the market in the North America region can be attributed to several factors. Firstly, there have been substantial investments to modernize pathology infrastructure in the region, which is driving market growth. Additionally, there is an increasing adoption of digital pathology solutions in North America, contributing to the overall market expansion. Moreover, the continuous expansion of the healthcare infrastructure and the growing availability of advanced AI technologies in the market are further boosting the growth in this region. The increasing focus on technology, patient safety, and quality improvement, combined with technological advancements in medical devices and government initiatives, continues to drive the adoption of AI in pathology market in North America.
The break-down of primary participants is as mentioned below:
- By Company Type – Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
- By Designation – C-level: 42%, Director-level: 31%, and Others: 27%
- By Region – North America: 32%, Asia Pacific: 26%, Europe: 32%, Middle East & Africa: 5%, Latin America: 5%
Key Players in the AI in Pathology Market
The key players functioning in the AI in pathology market include Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US), Akoya Biosciences, Inc. (US), Aiforia Technologies Plc (Finland), Indica Labs Inc. (US), OptraScan (US), Ibex Medical Analytics Ltd. (Israel), Mindpeak GmbH (Germany), Tribun Health (France), Techcyte, Inc. (US), Deep Bio Inc. (Korea), Lumea Inc. (US), Visiopharm (Denmark), aetherAI (Taiwan), Aiosyn (Netherlands), Paige AI, Inc. (US), Proscia Inc. (US), PathAI, Inc. (US), Tempus Labs, Inc. (US), Konfoong Biotech International Co., Ltd. (China), DoMore Diagnostics AS (Norway), Verily Life Sciences, LLC (US), deepPath (US), and 4D Path Inc (US).
Research Coverage:
The report analyses the AI in pathology market. It aims to estimate the market size and future growth potential of various market segments based on components, neural network, application, end-user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms and new entrants/smaller firms to gauge the market’s pulse, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
- Analysis of key drivers: (Increasing adoption of AI in pathology to enhance lab efficiency, growing digitization of pathology, augmenting telepathology with AI advancements, rise in cases of misdiagnoses, and technology advancements in deep learning enabling synergy with artificial intelligence (AI) in pathology space), restraints (high cost of digital pathology systems, lack of skilled AI workforce and ambiguous regulatory guidelines for medical software), opportunities (growing demand of personalized medicines, shortage of skilled pathologists), and challenges (lack of sufficient data to train the AI algorithms, data privacy concerns, lack of transparency and interoperability) influencing the growth of the AI in pathology market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in pathology market.
- Market Development: Comprehensive information on the lucrative emerging markets, component, neural network, applications, end-user, and region.
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the AI in pathology market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the AI in pathology market like Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US).
目次
Table of Contents
1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
1.2.1 INCLUSIONS AND EXCLUSIONS 25
1.3 MARKETS COVERED 25
1.3.1 AI IN PATHOLOGY MARKET SEGMENTATION, BY REGION 26
1.3.2 YEARS CONSIDERED 26
1.4 CURRENCY CONSIDERED 26
1.5 STAKEHOLDERS 27
1.6 RECESSION IMPACT 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH APPROACH 28
FIGURE 1 RESEARCH DESIGN 28
2.1.1 SECONDARY RESEARCH 28
2.1.1.1 Key data from secondary sources 29
2.1.2 PRIMARY DATA 30
FIGURE 2 PRIMARY SOURCES 30
2.1.2.1 Key data from primary sources 31
2.1.2.2 Insights from primary experts 32
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 32
2.2 MARKET SIZE ESTIMATION 33
FIGURE 4 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 33
FIGURE 5 AI IN PATHOLOGY MARKET: CAGR PROJECTIONS 34
2.2.1 TOP-DOWN APPROACH 35
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 36
FIGURE 6 DATA TRIANGULATION METHODOLOGY 36
2.4 MARKET RANKING ANALYSIS 37
2.5 STUDY ASSUMPTIONS 37
2.6 LIMITATIONS 37
2.6.1 METHODOLOGY-RELATED LIMITATIONS 37
2.6.2 SCOPE-RELATED LIMITATIONS 37
2.7 RISK ASSESSMENT 38
TABLE 1 AI IN PATHOLOGY MARKET: RISK ASSESSMENT 38
2.8 RECESSION IMPACT ANALYSIS 38
3 EXECUTIVE SUMMARY 39
FIGURE 7 AI IN PATHOLOGY MARKET, BY COMPONENT, 2023 VS. 2028 (USD MILLION) 39
FIGURE 8 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023 VS. 2028 (USD MILLION) 40
FIGURE 9 AI IN PATHOLOGY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 41
FIGURE 10 AI IN PATHOLOGY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 42
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF AI IN PATHOLOGY MARKET 43
4 PREMIUM INSIGHTS 44
4.1 AI IN PATHOLOGY MARKET OVERVIEW 44
FIGURE 12 GROWING DIGITIZATION OF PATHOLOGY TO DRIVE MARKET GROWTH 44
4.2 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COMPONENT AND COUNTRY 45
FIGURE 13 SOFTWARE SEGMENT TO COMMAND LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023 45
4.3 GEOGRAPHIC SNAPSHOT OF AI IN PATHOLOGY MARKET 46
FIGURE 14 MARKET IN UK TO GROW AT HIGHEST CAGR 46
4.4 REGIONAL MIX: AI IN PATHOLOGY MARKET 46
FIGURE 15 NORTH AMERICA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 46
4.5 AI IN PATHOLOGY MARKET: DEVELOPED VS. DEVELOPING MARKETS 47
FIGURE 16 DEVELOPED MARKETS TO REGISTER HIGHER GROWTH RATES 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS 48
FIGURE 17 AI IN PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48
TABLE 2 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: IMPACT ANALYSIS 49
5.2.1 DRIVERS 49
5.2.1.1 Increasing number of partnerships and collaborations among players to develop and launch advanced AI in pathology solutions 49
5.2.1.2 Growing digitalization of pathology 50
5.2.1.3 Growing cases of misdiagnoses 51
5.2.1.4 Augmenting telepathology with AI advancements 51
5.2.1.5 Technological advancements in deep learning 52
5.2.2 RESTRAINTS 52
5.2.2.1 High cost of digital pathology systems 52
5.2.2.2 Shortage of skilled AI workforce and ambiguous regulatory guidelines for medical software 52
5.2.3 OPPORTUNITIES 53
5.2.3.1 Growing demand for personalized medicine 53
TABLE 3 US: GROWTH IN NUMBER OF PERSONALIZED MEDICINES (2008–2020) 54
FIGURE 18 FDA-APPROVED PERSONALIZED MEDICINES, 2015–2021 54
5.2.3.2 Shortage of skilled pathologists 54
TABLE 4 NUMBER OF INHABITANTS PER PATHOLOGIST, BY COUNTRY, 2020 55
5.2.4 CHALLENGES 55
5.2.4.1 Lack of sufficient data to train AI algorithms 55
5.2.4.2 Data privacy concerns 56
FIGURE 19 HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF HEALTH AND HUMAN SERVICES, 2021 56
5.2.4.3 Lack of transparency and interoperability 56
6 INDUSTRY INSIGHTS 57
6.1 INDUSTRY TRENDS 57
6.1.1 IMPROVED QUALITY CONTROL WITH ARTIFICIAL INTELLIGENCE 57
6.1.2 TRANSFORMATION IN STAINING TECHNIQUES 57
6.2 INCREASING INVESTMENTS FOR AI IN PATHOLOGY 58
6.3 TECHNOLOGY ANALYSIS 58
6.3.1 MACHINE LEARNING (ML) AND DEEP LEARNING (DL) 58
6.3.2 IMAGE ANALYSIS AND COMPUTER VISION 58
6.3.3 NATURAL LANGUAGE PROCESSING (NLP) 58
6.3.4 DATA INTEGRATION AND FUSION 59
6.3.5 AUGMENTED PATHOLOGY AND DECISION SUPPORT SYSTEMS 59
6.3.6 PREDICTIVE ANALYTICS AND PROGNOSTIC MODELS 59
6.3.7 CLOUD COMPUTING AND BIG DATA INFRASTRUCTURE 59
6.4 PORTER’S FIVE FORCES ANALYSIS 60
FIGURE 20 AI IN PATHOLOGY MARKET MARKED BY MODERATE TO HIGH COMPETITIVE INTENSITY AMONG MARKET PLAYERS 60
TABLE 5 AI IN PATHOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 61
6.4.1 THREAT OF NEW ENTRANTS 61
6.4.2 THREAT OF SUBSTITUTES 61
6.4.3 BARGAINING POWER OF SUPPLIERS 61
6.4.4 BARGAINING POWER OF BUYERS 61
6.4.5 INTENSITY OF COMPETITIVE RIVALRY 62
6.5 REGULATORY ANALYSIS 62
6.5.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
TABLE 6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
6.5.2 REGULATORY ANALYSIS, BY REGION 63
6.5.2.1 North America 63
6.5.2.1.1 US 63
TABLE 7 US FDA: MEDICAL DEVICE CLASSIFICATION 63
TABLE 8 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 63
6.5.2.1.2 Canada 64
TABLE 9 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 64
6.5.2.2 Europe 64
TABLE 10 EUROPE: CLASSIFICATION OF IVD DEVICES 65
FIGURE 21 EUROPE: IVDR TIMELINE 65
6.5.2.3 Asia Pacific 66
6.5.2.3.1 Japan 66
TABLE 11 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 66
6.5.2.3.2 China 66
TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES 67
6.6 VALUE-CHAIN ANALYSIS 67
FIGURE 22 VALUE-CHAIN ANALYSIS (2022) 67
6.7 ECOSYSTEM 68
FIGURE 23 AI IN PATHOLOGY MARKET: ECOSYSTEM 69
6.8 PATENT ANALYSIS 69
6.8.1 PATENT PUBLICATION TRENDS FOR AI IN PATHOLOGY SOLUTIONS 69
FIGURE 24 NUMBER OF PATENTS PUBLISHED, JANUARY 2013 TO MAY 2023 70
6.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS 70
FIGURE 25 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR AI IN PATHOLOGY PATENTS (JANUARY 2013 TO MAY 2023) 71
FIGURE 26 TOP APPLICANT COUNTRIES/REGIONS FOR AI IN PATHOLOGY PATENTS (JANUARY 2013 TO MAY 2023) 72
6.9 KEY CONFERENCES AND EVENTS, 2023–2024 72
TABLE 13 AI IN PATHOLOGY MARKET: LIST OF CONFERENCES AND EVENTS 72
6.10 CASE STUDY ANALYSIS 73
6.10.1 CASE STUDY 1: PATHAI USES PYTORCH TO IMPROVE PATIENT OUTCOMES WITH AI-POWERED PATHOLOGY 73
6.10.2 CASE STUDY 2: COMBATING CERVICAL CANCER WITH AI 73
6.11 PRICING ANALYSIS 74
6.12 KEY STAKEHOLDERS AND BUYING CRITERIA 75
6.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 75
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN PATHOLOGY PRODUCTS 75
TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN PATHOLOGY PRODUCTS (%) 75
6.12.2 BUYING CRITERIA 76
FIGURE 28 KEY BUYING CRITERIA FOR AI IN PATHOLOGY PRODUCTS 76
TABLE 15 KEY BUYING CRITERIA FOR AI IN PATHOLOGY PRODUCTS 76
7 AI IN PATHOLOGY MARKET, BY COMPONENT 77
7.1 INTRODUCTION 78
TABLE 16 AI IN PATHOLOGY MARKET, BY COMPONENT, 2021–2028 (USD MILLION) 78
7.2 SOFTWARE 78
7.2.1 INTELLIGENT SOFTWARE HELPS REDUCE ERRORS CAUSED BY STANDARD PATHOLOGY APPROACHES 78
TABLE 17 AI IN PATHOLOGY SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79
7.3 SCANNERS 79
7.3.1 USE OF AI IN SCANNERS ENHANCES SCANNING PROCESS AND IMPROVES IMAGE QUALITY 79
TABLE 18 AI IN PATHOLOGY SCANNERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
8 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK 81
8.1 INTRODUCTION 82
TABLE 19 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021–2028 (USD MILLION) 82
8.2 CONVOLUTIONAL NEURAL NETWORKS 82
8.2.1 CONVOLUTIONAL NEURAL NETWORKS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 82
TABLE 20 AI IN PATHOLOGY MARKET FOR CONVOLUTIONAL NEURAL NETWORKS, BY COUNTRY, 2021–2028 (USD MILLION) 83
8.3 GENERATIVE ADVERSARIAL NETWORKS 83
8.3.1 GENERATED SYNTHETIC PATHOLOGY IMAGES CLOSELY RESEMBLE REAL PATHOLOGY 83
TABLE 21 AI IN PATHOLOGY MARKET FOR GENERATIVE ADVERSARIAL NETWORKS, BY COUNTRY, 2021–2028 (USD MILLION) 84
8.4 RECURRENT NEURAL NETWORKS 85
8.4.1 ABILITY OF RECURRENT NEURAL NETWORKS TO ANALYZE TIME-DEPENDENT PATTERNS TO PROPEL GROWTH 85
TABLE 22 AI IN PATHOLOGY MARKET FOR RECURRENT NEURAL NETWORKS, BY COUNTRY, 2021–2028 (USD MILLION) 86
8.5 OTHER NEURAL NETWORKS 86
TABLE 23 AI IN PATHOLOGY MARKET FOR OTHER NEURAL NETWORKS, BY COUNTRY, 2021–2028 (USD MILLION) 87
9 AI IN PATHOLOGY MARKET, BY APPLICATION 88
9.1 INTRODUCTION 89
TABLE 24 AI IN PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 89
9.2 DRUG DISCOVERY 89
9.2.1 DRUG DISCOVERY SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 89
TABLE 25 APPLICATIONS OF AI IN PATHOLOGY IN DRUG DISCOVERY 90
TABLE 26 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION) 91
9.3 DISEASE DIAGNOSIS AND PROGNOSIS 91
9.3.1 GROWING USE OF AI AND ML FOR DIAGNOSTIC AND PROGNOSTIC PURPOSES TO PROPEL GROWTH 91
TABLE 27 AI IN PATHOLOGY MARKET FOR DISEASE DIAGNOSIS AND PROGNOSIS, BY COUNTRY, 2021–2028 (USD MILLION) 92
9.4 CLINICAL WORKFLOW OPTIMIZATION 93
9.4.1 ADVANTAGES OF AI IN ENHANCING CLINICAL WORKFLOWS BY AUTOMATING REPETITIVE TASKS TO DRIVE GROWTH 93
TABLE 28 AI IN PATHOLOGY MARKET FOR CLINICAL WORKFLOW OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 94
9.5 TRAINING AND EDUCATION 94
9.5.1 APPLICATIONS IN IMPROVING TRAINING AND EDUCATION PROVIDED TO PATHOLOGISTS IN ACADEMIC INSTITUTES TO DRIVE GROWTH 94
TABLE 29 AI IN PATHOLOGY MARKET FOR TRAINING AND EDUCATION, BY COUNTRY, 2021–2028 (USD MILLION) 95
10 AI IN PATHOLOGY MARKET, BY END USER 96
10.1 INTRODUCTION 97
TABLE 30 AI IN PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 97
10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 97
10.2.1 RISING USE OF AI-BASED DIGITAL PATHOLOGY SOLUTIONS IN DRUG DEVELOPMENT TO DRIVE GROWTH 97
TABLE 31 AI IN PATHOLOGY MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 98
10.3 HOSPITALS AND REFERENCE LABORATORIES 98
10.3.1 RISING NUMBER OF HOSPITALIZATIONS DUE TO INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE GROWTH 98
TABLE 32 AI IN PATHOLOGY MARKET FOR HOSPITALS AND REFERENCE LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 99
10.4 ACADEMIC AND RESEARCH INSTITUTES 99
10.4.1 INCREASING INVESTMENTS FOR RESEARCH IN DISEASE DIAGNOSIS TO SUPPORT GROWTH 99
TABLE 33 AI IN PATHOLOGY MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 100
11 AI IN PATHOLOGY MARKET, BY REGION 101
11.1 INTRODUCTION 102
TABLE 34 AI IN PATHOLOGY MARKET, BY REGION, 2021–2028 (USD MILLION) 102
11.2 NORTH AMERICA 103
FIGURE 29 NORTH AMERICA: AI IN PATHOLOGY MARKET SNAPSHOT 103
TABLE 35 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 36 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021–2028 (USD MILLION) 104
TABLE 37 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021–2028 (USD MILLION) 104
TABLE 38 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 105
TABLE 39 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 105
11.2.1 NORTH AMERICA: RECESSION IMPACT 105
11.2.2 US 106
11.2.2.1 US to dominate North American market during forecast period 106
TABLE 40 US: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021–2028 (USD MILLION) 107
TABLE 41 US: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021–2028 (USD MILLION) 108
TABLE 42 US: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 108
TABLE 43 US: AI IN PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 109
11.2.3 CANADA 109
11.2.3.1 Increasing research in pathology to drive growth 109
TABLE 44 CANADA: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021–2028 (USD MILLION) 110
TABLE 45 CANADA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021–2028 (USD MILLION) 110
TABLE 46 CANADA: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110
TABLE 47 CANADA: AI IN PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 111
11.3 EUROPE 111
TABLE 48 EUROPE: AI IN PATHOLOGY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 49 EUROPE: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021–2028 (USD MILLION) 112
TABLE 50 EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021–2028 (USD MILLION) 112
TABLE 51 EUROPE: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 112
TABLE 52 EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 113
11.3.1 EUROPE: RECESSION IMPACT 113
11.3.2 UK 114
11.3.2.1 Adoption of AI in pathology for drug discovery to fuel growth 114
TABLE 53 UK: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021–2028 (USD MILLION) 114
TABLE 54 UK: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021–2028 (USD MILLION) 115
TABLE 55 UK: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 115
TABLE 56 UK: AI IN PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 116
11.3.3 GERMANY 116
11.3.3.1 Availability of funding for AI initiatives to boost growth 116
TABLE 57 GERMANY: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021–2028 (USD MILLION) 116
TABLE 58 GERMANY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021–2028 (USD MILLION) 117
TABLE 59 GERMANY: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 117
TABLE 60 GERMANY: AI IN PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 118
11.3.4 FRANCE 118
11.3.4.1 Increasing government funding and favorable insurance system to drive growth 118
TABLE 61 FRANCE: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021–2028 (USD MILLION) 119
TABLE 62 FRANCE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021–2028 (USD MILLION) 119
TABLE 63 FRANCE: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 119
TABLE 64 FRANCE: AI IN PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 120
11.3.5 REST OF EUROPE 120
TABLE 65 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021–2028 (USD MILLION) 121
TABLE 66 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021–2028 (USD MILLION) 121
TABLE 67 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 122
TABLE 68 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 122
11.4 ASIA PACIFIC 123
TABLE 69 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 70 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021–2028 (USD MILLION) 123
TABLE 71 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021–2028 (USD MILLION) 124
TABLE 72 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 124
TABLE 73 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 125
11.4.1 ASIA PACIFIC: RECESSION IMPACT 125
11.4.2 CHINA 126
11.4.2.1 Rising geriatric population to drive demand for AI in pathology products 126
TABLE 74 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 126
TABLE 75 CHINA: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021–2028 (USD MILLION) 127
TABLE 76 CHINA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021–2028 (USD MILLION) 127
TABLE 77 CHINA: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 127
TABLE 78 CHINA: AI IN PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 128
11.4.3 JAPAN 128
11.4.3.1 Advanced healthcare infrastructure to support market growth 128
TABLE 79 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 129
TABLE 80 JAPAN: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021–2028 (USD MILLION) 129
TABLE 81 JAPAN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021–2028 (USD MILLION) 129
TABLE 82 JAPAN: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 130
TABLE 83 JAPAN: AI IN PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 130
11.4.4 REST OF ASIA PACIFIC 130
TABLE 84 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021–2028 (USD MILLION) 131
TABLE 85 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021–2028 (USD MILLION) 132
TABLE 86 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 132
TABLE 87 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 133
11.5 LATIN AMERICA 133
TABLE 88 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021–2028 (USD MILLION) 134
TABLE 89 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021–2028 (USD MILLION) 134
TABLE 90 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 134
TABLE 91 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 135
11.5.1 LATIN AMERICA: RECESSION IMPACT 135
11.6 MIDDLE EAST & AFRICA 136
TABLE 92 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY COMPONENT, 2021–2028 (USD MILLION) 137
TABLE 93 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2021–2028 (USD MILLION) 137
TABLE 94 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 138
TABLE 95 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 138
11.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT 139
12 COMPETITIVE LANDSCAPE 140
12.1 INTRODUCTION 140
12.2 STRATEGIES OF KEY PLAYERS/RIGHT TO WIN 140
FIGURE 30 KEY DEVELOPMENTS UNDERTAKEN BY MAJOR PLAYERS BETWEEN JANUARY 2020 AND MAY 2023 141
12.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS, 2022 142
FIGURE 31 REVENUE ANALYSIS OF KEY PLAYERS 142
12.4 MARKET RANKING ANALYSIS 142
FIGURE 32 AI IN PATHOLOGY MARKET RANKING ANALYSIS OF KEY PLAYERS (2022) 143
12.5 COMPETITIVE BENCHMARKING 144
TABLE 96 FOOTPRINT ANALYSIS OF COMPANIES 144
TABLE 97 PRODUCT FOOTPRINT ANALYSIS (25 COMPANIES) 145
TABLE 98 APPLICATION FOOTPRINT ANALYSIS (25 COMPANIES) 146
TABLE 99 REGIONAL FOOTPRINT ANALYSIS (25 COMPANIES) 147
12.6 COMPANY EVALUATION MATRIX 148
12.6.1 STARS 148
12.6.2 PERVASIVE PLAYERS 148
12.6.3 EMERGING LEADERS 148
12.6.4 PARTICIPANTS 148
FIGURE 33 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX, 2022 149
12.7 COMPANY EVALUATION MATRIX FOR START-UP/SME PLAYERS 150
12.7.1 PROGRESSIVE COMPANIES 150
12.7.2 DYNAMIC COMPANIES 150
12.7.3 STARTING BLOCKS 150
12.7.4 RESPONSIVE COMPANIES 150
FIGURE 34 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX FOR START-UP/SME PLAYERS, 2022 151
12.8 COMPETITIVE SCENARIO AND TRENDS 152
12.8.1 PRODUCT LAUNCHES AND APPROVALS 152
TABLE 100 AI IN PATHOLOGY MARKET: PRODUCT LAUNCHES AND APPROVALS, 2020–2023 152
12.8.2 DEALS 152
TABLE 101 AI IN PATHOLOGY MARKET: DEALS, 2020–2023 152
12.8.3 OTHER DEVELOPMENTS 153
TABLE 102 AI IN PATHOLOGY MARKET: OTHER DEVELOPMENTS, 2020–2023 153
13 COMPANY PROFILES 154
13.1 KEY PLAYERS 154
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 KONINKLIJKE PHILIPS N.V. 154
TABLE 103 KONINKLIJKE PHILIPS N.V.: BUSINESS OVERVIEW 154
FIGURE 35 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022) 155
13.1.2 F. HOFFMANN-LA ROCHE LTD. 157
TABLE 104 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 157
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 158
13.1.3 HOLOGIC, INC. 161
TABLE 105 HOLOGIC, INC.: BUSINESS OVERVIEW 161
FIGURE 37 HOLOGIC, INC.: COMPANY SNAPSHOT (2022) 162
13.1.4 AKOYA BIOSCIENCES, INC. 164
TABLE 106 AKOYA BIOSCIENCES, INC.: BUSINESS OVERVIEW 164
FIGURE 38 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2022) 165
13.1.5 AIFORIA TECHNOLOGIES PLC 167
TABLE 107 AIFORIA TECHNOLOGIES PLC: BUSINESS OVERVIEW 167
FIGURE 39 AIFORIA TECHNOLOGIES PLC: COMPANY SNAPSHOT (2022) 167
13.1.6 INDICA LABS INC. 169
TABLE 108 INDICA LABS INC.: BUSINESS OVERVIEW 169
13.1.7 OPTRASCAN, INC. 171
TABLE 109 OPTRASCAN, INC.: BUSINESS OVERVIEW 171
13.1.8 IBEX MEDICAL ANALYTICS LTD. 172
TABLE 110 IBEX MEDICAL ANALYTICS LTD.: BUSINESS OVERVIEW 172
13.1.9 MINDPEAK GMBH 175
TABLE 111 MINDPEAK GMBH: BUSINESS OVERVIEW 175
13.1.10 TRIBUN HEALTH 177
TABLE 112 TRIBUN HEALTH: BUSINESS OVERVIEW 177
13.1.11 TECHCYTE, INC. 179
TABLE 113 TECHCYTE, INC.: BUSINESS OVERVIEW 179
13.1.12 DEEP BIO INC. 181
TABLE 114 DEEP BIO INC.: BUSINESS OVERVIEW 181
13.1.13 LUMEA INC. 182
TABLE 115 LUMEA INC.: BUSINESS OVERVIEW 182
13.1.14 VISIOPHARM 183
TABLE 116 VISIOPHARM: BUSINESS OVERVIEW 183
13.1.15 AETHER AI 185
TABLE 117 AETHER AI: BUSINESS OVERVIEW 185
13.1.16 AIOSYN 186
TABLE 118 AIOSYN: BUSINESS OVERVIEW 186
13.1.17 PAIGE AI, INC. 187
TABLE 119 PAIGE AI, INC.: BUSINESS OVERVIEW 187
13.1.18 PROSCIA, INC. 189
TABLE 120 PROSCIA, INC.: BUSINESS OVERVIEW 189
13.1.19 PATHAI, INC. 191
TABLE 121 PATHAI, INC.: BUSINESS OVERVIEW 191
13.1.20 TEMPUS LABS, INC. 193
TABLE 122 TEMPUS LABS, INC.: BUSINESS OVERVIEW 193
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS 194
13.2.1 KONFOONG BIOINFORMATION TECH CO., LTD. 194
13.2.2 DOMORE DIAGNOSTICS AS 194
13.2.3 VERILY LIFE SCIENCES, LLC 194
13.2.4 DEEPPATH 195
13.2.5 4D PATH INC. 195
14 APPENDIX 196
14.1 DISCUSSION GUIDE 196
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 200
14.3 CUSTOMIZATION OPTIONS 202
14.4 RELATED REPORTS 202
14.5 AUTHOR DETAILS 203